Latigo Biotherapeutics
Latest round
- Series B
Last raised
- Jan 2025
Total raised
- $200M
Investors
- 14
About Latigo Biotherapeutics
Established in 2020 and based in California, US, Latigo Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops non-opioid pain drugs. The company was founded by Sean Harper. In February 2024, Latigo Biotherapeutics, Inc. Latigo Biotherapeutics develops non-opioid pain medicines.8 inhibitor.
Who invested in Latigo Biotherapeutics
14 investors across 3 rounds
See all investors in Latigo Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Latigo Biotherapeutics
Who invested in Latigo Biotherapeutics?
Latigo Biotherapeutics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Latigo Biotherapeutics raised?
Latigo Biotherapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Latigo Biotherapeutics last raise money?
Latigo Biotherapeutics's most recent round on record is a Series B, in Jan 2025.
What does Latigo Biotherapeutics do?
Established in 2020 and based in California, US, Latigo Biotherapeutics, Inc.
Where is Latigo Biotherapeutics headquartered?
Latigo Biotherapeutics is headquartered in Thousand Oaks, US.
Which VCs invest in companies like Latigo Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Latigo Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Latigo Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.